Replies to post #244741 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

And again, in that chemoradiotherpay trial, the very small IDH1 mutated and methylated subgroup, which is typically a sub-type of proneural, which typically arises in young people, at most impacted 12 patients in that trial, potentially six or less of which lived five years, with only three patients out of larger GBM cross-section 100 alive approximately eight years after end of study. Only nine patients out of that 100 larger GBM cross section lived three years. Even worse than typical for SOC.

Limitation: I have not read beyond their abstract.